norketotifen
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2018 (NCT03712163)
Timeline
Indications
Mechanism of action
- Histamine H1 receptorBLOCKER
HRH1 blocker
Chemistry & pharmacology
Loading structure…
SMILES
O=C1Cc2ccccc2C(=C2CCNCC2)c2ccsc21- Mol. weight
- 295.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1197564 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04610047 | Phase 2 | Dec 1, 2020 | Emergo Therapeutics, Inc. |
| NCT04043923 | Phase 2 | Oct 1, 2019 | Emergo Therapeutics, Inc. |
| NCT03887026 | Phase 2 | Apr 1, 2019 | Emergo Therapeutics, Inc. |
| NCT03712163 | Phase 1 | Oct 15, 2018 | Emergo Therapeutics, Inc., Worldwide Clinical Trials |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emergo Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2018 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1